<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diseases potentially acquired by travel to Central Africa</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diseases potentially acquired by travel to Central Africa</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diseases potentially acquired by travel to Central Africa</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Murdoch, MD, MSc, DTM&amp;H, FRACP, FRCPA, FFSc(RCPA)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H16189722"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Central Africa is comprised of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fangola&amp;token=Z%2BoZO6TMLcOSxW%2FRgtuIX5UqfW%2B9JO0rtL6uBgbTcNALOtFpKWAwe9apFpCVNk6NMa%2Bc%2Fk%2B6jnKd8Ktwf2amiw%3D%3D&amp;TOPIC_ID=96985" target="_blank">Angola</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fcameroon&amp;token=ji0%2BmOYDPAt%2B5%2BI9fEHssLHFYCh%2BuP%2BhhYmrtnI%2FSDP0usip9IBY%2B5jqe5YO%2FlBz2OFin2oAMbxMNpI%2F26Ylyw%3D%3D&amp;TOPIC_ID=96985" target="_blank">Cameroon</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fcentral-african-republic&amp;token=dy5BK9Bn9WLNo1Z0dzEoPgFYgvrJNTAZAOPe79xzo3Vi29bsgF%2B7e4SpgB53%2BM%2F4aUkvilJyeHE2wgzmZGvwbGR2vhdOzddvj8WZRO0qCvQ%3D&amp;TOPIC_ID=96985" target="_blank">Central African Republic</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fchad&amp;token=VF%2FmP5yR1eVjq1w2SqwN70bmBTLI%2BwHiVh5YPuRPNXE%2FW1h%2BX4X23sTvovLxogUhSW6cQ7e96nngHwHE5sn68g%3D%3D&amp;TOPIC_ID=96985" target="_blank">Chad</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fcongo&amp;token=RXNa2kL2%2BtlsEGVOA0uPRGB%2FfYN2HewwchmLPTe62BQA2YwyNmopQwzr6h1fNtcrsSbeRLNTf3%2F9VKsw9MvWJg%3D%3D&amp;TOPIC_ID=96985" target="_blank">Congo</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fequatorial-guinea&amp;token=tTv2YF1H7Rw9nehbVV4QP4c8NLzBBTVPDewdL8qEJaBs32SXhihtpDaEmxeYrdzukg0SY60wPe3DuhhsC5z7%2FiXSav4uKwidGLv6Qyjjk50%3D&amp;TOPIC_ID=96985" target="_blank">Equatorial Guinea</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fgabon&amp;token=Z%2BoZO6TMLcOSxW%2FRgtuIXzZHmxtGw6AuMTmlkrWgXCRteSDJWfTIztO%2BZQsAVTgTgAwrrl4DTMrMjv4pbFrb4w%3D%3D&amp;TOPIC_ID=96985" target="_blank">Gabon</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fsouth-sudan&amp;token=8l5YwxhmXSjTB03G7RxfZNqr1motFb9uKNLnlyIRMcmiPkXj13QsOxSigGlYQH6rmEPfcy5U26%2BN8ZF%2Bm3n0vcAtyLFm%2F94W%2BFaQhxlotfk%3D&amp;TOPIC_ID=96985" target="_blank">South Sudan</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fsudan&amp;token=ji0%2BmOYDPAt%2B5%2BI9fEHssIZW22gxHmQzaq%2BZFGu3SqlVBkcxJHUdh8HdJ6arJEnmSSWmShMMqbmtzNoZwu2vsw%3D%3D&amp;TOPIC_ID=96985" target="_blank">Sudan</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fdemocratic-republic-of-congo&amp;token=Po09YYrpNM9rAq1Qq9bb%2FbZlA45M6%2Fif5t4ClRjGKVoT7j4BW0DzCpcKh0WhqBAocWOSOwY%2Fv6A3E6rly4Fcq0lwgFWWTqftyJYCswV4M2g%3D&amp;TOPIC_ID=96985" target="_blank">Democratic Republic of Congo (Zaire)</a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fdestinations%2Ftraveler%2Fnone%2Fzambia&amp;token=FquSN2b8B9EPZtSBJg3jbIUhj2ATR6gMZlG0Nt%2B1IqXnHvoD3vCFYWJhmCSWVjC6CnrQvlZMioKXEf7aXfzlb68AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=96985" target="_blank">Zambia</a>. This region encompasses tropical rain forests, desert areas, and wooded areas.</p><p class="headingAnchor" id="H16189728"><span class="h1">ARTHROPOD-BORNE DISEASES</span></p><p class="headingAnchor" id="H16189735"><span class="h2">Malaria</span><span class="headingEndMark"> — </span>Malaria is a major risk for travelers to Central Africa. Endemic areas exist in all countries in this region. <em>Plasmodium falciparum</em> is the predominant cause of malaria, and <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> resistance is widespread. Within endemic areas, transmission occurs year round [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Angola – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cameroon – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central African Republic – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chad – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congo – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Equatorial Guinea – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gabon – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>South Sudan – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sudan – Risk throughout the year in the whole country.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Democratic Republic of Congo (Zaire) – Risk throughout the year in the whole country</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Zambia – Risk throughout the year in the whole country</p><p></p><p>Issues related to prevention of malaria in travelers are discussed separately. (See  <a class="medical medical_review" href="/d/html/5722.html" rel="external">"Prevention of malaria infection in travelers"</a>.)</p><p class="headingAnchor" id="H16189742"><span class="h2">Yellow fever</span><span class="headingEndMark"> — </span>Yellow fever is endemic throughout most of Central Africa [<a href="#rid2">2</a>]. Several species of mosquitoes are the reservoir of yellow fever virus and transmit infection to monkeys as well as humans. In Africa, the main mosquito vectors are <em>Aedes aegypti</em> and <em>Aedes simpsoni</em>. (See  <a class="medical medical_review" href="/d/html/3032.html" rel="external">"Yellow fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Three types of transmission cycle for yellow fever exist:</p><p class="bulletIndent1"><span class="glyph">●</span>Sylvatic (jungle) yellow fever occurs among monkeys in tropical rain forests; sporadic cases occur in humans who enter the forest.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate yellow fever occurs in semi-humid savannas where semi-domestic mosquitoes infect both humans and monkeys and cause small-scale epidemics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urban yellow fever occurs when migrants introduce the virus into areas of high human population density, resulting in large epidemics.</p><p></p><p><a class="drug drug_general" data-topicid="10051" href="/d/drug information/10051.html" rel="external">Yellow fever vaccine</a> is required for entry into most countries in Central Africa. In addition, many neighboring countries of endemic regions require yellow fever certificates for travelers coming from infected areas. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Yellow fever vaccine'</a> and  <a class="medical medical_review" href="/d/html/129108.html" rel="external">"Yellow fever: Treatment and prevention", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H16189749"><span class="h2">Dengue</span><span class="headingEndMark"> — </span>Many areas in Central Africa are suitable for dengue virus transmission. (See  <a class="medical medical_review" href="/d/html/3030.html" rel="external">"Dengue virus infection: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H16189756"><span class="h2">Other viral hemorrhagic fevers</span><span class="headingEndMark"> — </span>In addition to yellow fever and dengue, several other viral hemorrhagic fevers have caused localized outbreaks in Africa. Of particular relevance to Central Africa are Ebola, Marburg hemorrhagic fever, and Crimean-Congo hemorrhagic fever (CCHF).</p><p class="headingAnchor" id="H16189763"><span class="h3">Ebola virus</span><span class="headingEndMark"> — </span>Ebola virus was first identified in Sudan and Democratic Republic of Congo (Zaire) in 1976 [<a href="#rid3">3</a>]. Transmission occurs through direct contact with body fluid from infected individuals. Mortality rates differ among Ebola viruses isolated from different regions; mortality rates of 70 to 90 percent were seen in association with Democratic Republic of Congo (Zaire) Ebola virus infections but were lower with Sudan Ebola virus [<a href="#rid4">4</a>]. Variations in outcome during an epidemic may result from genetically determined differences in innate immune responses to the virus.</p><p>Serologic studies suggest that mild or asymptomatic episodes occur, although they are uncommon. A population-based serosurvey of more than 900 residents in Gabon found a seroprevalence of 1.4 percent [<a href="#rid5">5</a>].</p><p>The natural reservoir for Ebola virus may be bats; in a field study where more than 1000 small vertebrates were collected during Ebola outbreaks in humans and great apes, asymptomatic infection was identified in three species of fruit bats [<a href="#rid6">6</a>]. Human infection may be countered by educational programs, since local populations eat fruit bats where Ebola outbreaks have occurred. The outbreak of Ebola in the Democratic Republic of Congo in 2014 was not linked to the large outbreak in West Africa. In April 2022, an Ebola outbreak in Equateur Province of the Democratic Republic of Congo was declared. This is the third outbreak in the province since 2018. (See  <a class="medical medical_review" href="/d/html/3023.html" rel="external">"Epidemiology and pathogenesis of Ebola virus disease"</a>.)</p><p class="headingAnchor" id="H16189770"><span class="h3">Marburg virus</span><span class="headingEndMark"> — </span>Marburg hemorrhagic fever is a highly fatal disease caused by an RNA virus in the Filoviridae family [<a href="#rid7">7</a>]. Marburg virus infection is rare and limited to countries in Central Africa [<a href="#rid8">8</a>]. The reservoir of infection is unknown.</p><p>Marburg hemorrhagic fever was first identified in 1967 after an infectious disease physician in a university hospital in Marburg, Germany, saw patients with a severe febrile illness associated with hemorrhage and shock [<a href="#rid9">9</a>]. All the patients worked for a pharmaceutical manufacturer where they had contact with African green monkeys. The virus that was isolated was unrelated to any other known family of viruses and had a unique branching morphology.</p><p>Marburg virus can be transmitted to humans through direct contact with body fluids (eg, blood, saliva, and urine) of an infected person or animal or through unsterile injections [<a href="#rid9">9</a>]. Marburg virus appears to be easily transmissible since healthcare workers have also been infected. The virus can survive for as long as several days on contaminated surfaces. The incubation period is estimated to be 5 to 10 days.</p><p>Marburg virus infection presents acutely with fever, chills, headache, and myalgia. After about five days, symptoms progress to include nausea, vomiting, chest pain, sore throat, abdominal pain, and diarrhea. A maculopapular rash may also occur. Over time, signs and symptoms become increasingly severe and can include jaundice, weight loss, and delirium. Patients die from septic shock with massive hemorrhage and multiorgan failure.</p><p>A serosurvey of 121 household contacts suggests that mild or asymptomatic disease is rare [<a href="#rid10">10</a>]. Diagnosis of suspected Marburg infection is established on clinical and epidemiologic grounds and confirmed by polymerase chain reaction (PCR), antigen-capture enzyme-linked immunosorbent assay (ELISA), immunoglobulin (Ig)M ELISA, or virus isolation [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H16189777"><span class="h3">Crimean-Congo hemorrhagic fever</span><span class="headingEndMark"> — </span>Crimean-Congo hemorrhagic fever is a severe, potentially fatal disease in humans caused by CCHF virus [<a href="#rid11">11</a>]. The disease has been documented in parts of Africa, Asia, Eastern Europe, and the Middle East. In the Central African region, countries regarded as endemic for CCHF are Central African Republic, the Democratic Republic of Congo, South Sudan, and Sudan. Transmission to humans occurs through tick bites, contact with a patient with CCHF during the acute stage of infection, or contact with blood or tissue from infected livestock [<a href="#rid12">12</a>].</p><p>The typical course of CCHF has four distinct phases: incubation, prehemorrhagic, hemorrhagic, and convalescence [<a href="#rid13">13</a>]. The incubation period that follows a tick bite is usually short (three to seven days). The prehemorrhagic period is characterized by the sudden onset of fever, headache, myalgia, and dizziness [<a href="#rid14">14</a>]. Additional symptoms of diarrhea, nausea, and vomiting are also seen in some cases. After approximately three days, hemorrhagic manifestations from petechiae, large hematomas, and frank bleeding (vaginal, gastrointestinal, nose, urinary, and respiratory tracts) usually follow [<a href="#rid15">15</a>]. The convalescence period begins in survivors about 10 to 20 days after onset of illness. The case-fatality rates range from 3 to 30 percent; disseminated intravascular coagulation and vascular dysregulation are common in severe cases [<a href="#rid14">14</a>].</p><p>Ultrasound findings include hepatosplenomegaly, paraceliac lymphadenopathy, gallbladder wall thickening, and intraperitoneal and pleural effusion [<a href="#rid16">16</a>]. These become prominent on the third day of disease in some patients.</p><p>Viral isolation needs to be conducted in biosafety level four laboratories [<a href="#rid13">13</a>]. IgM and IgG antibodies are detectable by ELISA and immunofluorescence assays from about seven days after the onset of disease [<a href="#rid17">17</a>]. Specific IgM antibodies decline to undetectable levels approximately four months after presentation.</p><p>Treatment is mainly supportive. <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">Ribavirin</a> has been demonstrated to be effective in observational clinical studies [<a href="#rid14">14,18</a>]. Patients should be treated for 10 days (30 mg/kg as an initial loading dose, then 15 mg/kg every six hours for four days, and then 7.5 mg/kg every eight hours for six days) [<a href="#rid13">13</a>].</p><p>Case-fatality rates range from 3 to 30 percent; disseminated intravascular coagulation and vascular dysregulation are commonly seen in severe cases [<a href="#rid14">14</a>]. Higher serum levels of proinflammatory cytokines interleukin (IL-) 6 and tumor necrosis factor (TNF) were demonstrated in patients with fatal infection than in those who survived [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H16189784"><span class="h2">African trypanosomiasis</span><span class="headingEndMark"> — </span>African trypanosomiasis (sleeping sickness) is endemic throughout much of Central Africa. Countries with the highest endemicity include Angola, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of Congo, South Sudan, and Sudan. (See  <a class="medical medical_review" href="/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/5697.html" rel="external">"Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Two different species of parasite cause two epidemiologically distinct diseases, both of which are transmitted by tsetse flies:</p><p class="bulletIndent1"><span class="glyph">●</span>West African trypanosomiasis is caused by <em>Trypanosoma brucei gambiense</em>. Humans are the primary reservoir, it occurs mainly in wooded areas along rivers, and tourists are rarely infected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>East African trypanosomiasis is caused by <em>Trypanosoma brucei rhodesiense</em>. Antelope and cattle are the primary reservoirs, it occurs mainly in savanna and woodland areas, and it has been reported in tourists visiting game parks [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H16189792"><span class="h2">Leishmaniasis</span><span class="headingEndMark"> — </span>Both cutaneous and visceral leishmaniasis occur in relatively restricted areas of South Sudan and Sudan. Sand flies of the genus <em>Phlebotomus</em> are the vectors. Visceral leishmaniasis occurs both sporadically and in epidemics. The main reservoirs are rodents and small carnivores. (See  <a class="medical medical_review" href="/d/html/87186.html" rel="external">"Cutaneous leishmaniasis: Epidemiology and control"</a> and  <a class="medical medical_review" href="/d/html/5690.html" rel="external">"Visceral leishmaniasis: Epidemiology and control"</a>.)</p><p class="headingAnchor" id="H16189799"><span class="h2">Onchocerciasis</span><span class="headingEndMark"> — </span>Onchocerciasis (river blindness) is caused by the roundworm <em>Onchocerca volvulus</em> and is transmitted to humans by <em>Simulium</em> black flies. Endemic areas are widespread through parts of Central Africa, determined by the distribution of the vector. Black flies breed in fast-flowing streams in both savanna and rainforest. The risk to short-term travelers of developing onchocerciasis is small, although acquisition after only four to six weeks' exposure has been documented [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/d/html/5683.html" rel="external">"Onchocerciasis"</a>.)</p><p class="headingAnchor" id="H16189806"><span class="h2">Rickettsioses</span><span class="headingEndMark"> — </span>Several rickettsioses are endemic in Central Africa [<a href="#rid23">23</a>]. Environments suitable for transmission of both epidemic typhus (caused by <em>Rickettsia prowazekii</em>) and murine typhus (caused by <em>Rickettsia typhi</em>) are present in Central Africa. Epidemic typhus is transmitted by the body louse. Conditions that favor the proliferation of lice include crowding in the setting of cold weather, war, and natural disasters. Murine typhus is transmitted to humans by rat or cat fleas and occurs most commonly in urban settings. (See  <a class="medical medical_review" href="/d/html/7906.html" rel="external">"Murine typhus"</a> and  <a class="medical medical_review" href="/d/html/7905.html" rel="external">"Epidemic typhus"</a>.)</p><p>In addition, tick typhus, caused by <em>Rickettsia conorii</em>, <em>Rickettsia africae</em>, and others, occurs sporadically, and its epidemiology is closely associated with ticks [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H175865095"><span class="h2">Chikungunya fever</span><span class="headingEndMark"> — </span>Chikungunya fever has been increasingly reported in the region [<a href="#rid25">25</a>], with outbreaks in Chad, Congo, and Sudan. Infection is transmitted by the bite of an <em>Aedes </em>mosquito, and the illness is characterized by sudden onset of fever and severe arthralgias. (See  <a class="medical medical_review" href="/d/html/3024.html" rel="external">"Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1961841660"><span class="h2">Zika virus</span><span class="headingEndMark"> — </span>Zika virus has been observed in Central Africa [<a href="#rid26">26-29</a>]. Symptoms of Zika virus infection include fever, rash, joint pain, and conjunctivitis. The illness is usually mild with symptoms lasting several days to a week; severe disease requiring hospitalization is uncommon. Asymptomatic infection is common, and only about one in five individuals who become infected with Zika virus become ill.</p><p>Zika is discussed further separately. (See  <a class="medical medical_review" href="/d/html/106169.html" rel="external">"Zika virus infection: An overview"</a>.)</p><p class="headingAnchor" id="H16189813"><span class="h1">FOODBORNE AND WATERBORNE DISEASES</span></p><p class="headingAnchor" id="H16189820"><span class="h2">Travelers' diarrhea</span><span class="headingEndMark"> — </span>Central Africa is a high-risk area for the development of travelers' diarrhea. Enterotoxigenic <em>Escherichia coli</em> is the most common pathogen identified [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/2709.html" rel="external">"Travelers' diarrhea: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H16189827"><span class="h2">Cholera</span><span class="headingEndMark"> — </span>Cholera outbreaks are frequent occurrences in Central Africa. (See  <a class="medical medical_review" href="/d/html/2704.html" rel="external">"Cholera: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H16189834"><span class="h2">Typhoid</span><span class="headingEndMark"> — </span>Typhoid fever is endemic throughout most of Central Africa, although the risk is generally less than in South Asia. (See  <a class="medical medical_review" href="/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2712.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Typhoid vaccine'</a>.)</p><p class="headingAnchor" id="H16189841"><span class="h2">Hepatitis A and E</span><span class="headingEndMark"> — </span>Hepatitis A virus is endemic throughout Central Africa. Hepatitis E has been responsible for both outbreaks and sporadic cases of hepatitis [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Hepatitis A vaccine'</a> and  <a class="medical medical_review" href="/d/html/3677.html" rel="external">"Hepatitis E virus infection"</a>.)</p><p class="headingAnchor" id="H16189856"><span class="h2">Schistosomiasis</span><span class="headingEndMark"> — </span>Schistosomiasis due to <em>Schistosoma haematobium</em> and <em>Schistosoma mansoni </em>is widespread in Central Africa [<a href="#rid32">32</a>]. Transmission occurs through exposure to fresh water (lakes and slow-moving rivers) in endemic regions. (See  <a class="medical medical_review" href="/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a>.)</p><p class="headingAnchor" id="H16189864"><span class="h2">Paragonimiasis</span><span class="headingEndMark"> — </span>Endemic foci of the lung fluke <em>Paragonimus westermani</em> are present in West and Central Africa. (See  <a class="medical medical_review" href="/d/html/5679.html" rel="external">"Paragonimiasis"</a>.)</p><p class="headingAnchor" id="H16189872"><span class="h2">Dracunculiasis</span><span class="headingEndMark"> — </span>Guinea worm (<em>Dracunculus medinensis</em>) infection was prevalent in the Central African region, but numbers of reported cases have fallen dramatically over years. A total of 54 cases were reported in 2019, all from Central Africa: Angola, Chad, South Sudan, and Cameroon [<a href="#rid33">33</a>]. The disease is associated with areas where people bathe and wade in water used also for drinking. (See  <a class="medical medical_review" href="/d/html/5694.html" rel="external">"Miscellaneous nematodes", section on 'Dracunculiasis'</a>.)</p><p class="headingAnchor" id="H16189880"><span class="h2">Echinococcosis</span><span class="headingEndMark"> — </span>Hydatid disease is relatively common in areas of Africa. (See  <a class="medical medical_review" href="/d/html/5669.html" rel="external">"Echinococcosis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H16189887"><span class="h1">OTHER INFECTIONS</span></p><p class="headingAnchor" id="H16189895"><span class="h2">Meningococcal disease</span><span class="headingEndMark"> — </span>Sub-Saharan Africa has a unique pattern of epidemic meningococcal disease. Epidemics occur during the dry season in the "meningitis belt"; the most affected countries are Chad, Nigeria, Burkina Faso, Mali, and Niger. Major epidemics occur every 5 to 10 years in this area, affecting hundreds of thousands of people. Most epidemics are caused by serogroup A and, less often, serogroup C. Both of these serogroups are covered by the polysaccharide meningococcal vaccine, which is recommended for travelers to countries affected by meningococcal outbreaks. (See  <a class="medical medical_review" href="/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection"</a> and  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Meningococcal vaccine'</a>.)</p><p class="headingAnchor" id="H16189902"><span class="h2">HIV infection</span><span class="headingEndMark"> — </span>Sub-Saharan Africa is the region of the world most affected by the HIV/AIDS pandemic. The main mode of transmission in the region is heterosexual contact. Unprotected sex with locals carries the greatest risk of transmission to travelers [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/3036.html" rel="external">"Global epidemiology of HIV infection"</a>.)</p><p class="headingAnchor" id="H16189910"><span class="h2">Other sexually transmitted diseases</span><span class="headingEndMark"> — </span>Sexually transmitted disease is a major public health problem in parts of Central Africa. Contact with sex workers involves high risk.</p><p class="headingAnchor" id="H16189918"><span class="h2">Hepatitis B and C</span><span class="headingEndMark"> — </span>Hepatitis B virus is highly endemic throughout Central Africa. (See  <a class="medical medical_review" href="/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history"</a>.)</p><p>The prevalence of hepatitis C is also high in many regions. (See  <a class="medical medical_review" href="/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/d/html/3650.html" rel="external">"Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults"</a>.)</p><p class="headingAnchor" id="H16189926"><span class="h2">Plague</span><span class="headingEndMark"> — </span>The majority of the world's reported cases of plague come from sub-Saharan Africa. (See  <a class="medical medical_review" href="/d/html/3143.html" rel="external">"Epidemiology, microbiology and pathogenesis of plague (<i>Yersinia pestis</i> infection)"</a> and  <a class="medical medical_review" href="/d/html/3131.html" rel="external">"Clinical manifestations, diagnosis, and treatment of plague (<i>Yersinia pestis</i> infection)"</a>.)</p><p class="headingAnchor" id="H16189933"><span class="h2">Rabies</span><span class="headingEndMark"> — </span>Rabies is endemic throughout Central Africa and has been reported with increasing frequency [<a href="#rid35">35</a>]. The domestic dog plays a key role in maintenance and transmission of rabies, although other animals (eg, mongoose and fox) are important in some regions. Postexposure treatment is recommended following all potential exposures, and prophylaxis should be considered by travelers spending significant periods of time in Central Africa. (See  <a class="medical medical_review" href="/d/html/8303.html" rel="external">"Rabies immune globulin and vaccine"</a> and  <a class="medical medical_review" href="/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis"</a> and  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Rabies vaccine'</a>.)</p><p class="headingAnchor" id="H16189941"><span class="h2">Tuberculosis</span><span class="headingEndMark"> — </span>Tuberculosis is relatively common in many parts of Central Africa, although short-term travelers from countries of low endemicity are generally not considered at increased risk of infection.</p><p class="headingAnchor" id="H16189949"><span class="h1">OTHER HAZARDS</span></p><p class="headingAnchor" id="H16189957"><span class="h2">Snake bites</span><span class="headingEndMark"> — </span>Venomous snakes are present throughout Central Africa. The most important species include the saw-scaled or carpet viper (<em>Echis</em> spp), puff adder (<em>Bitis arietans</em>), and spitting cobra (<em>Naja nigricollis</em>, <em>N. mossambica</em>, and others). (See  <a class="medical medical_review" href="/d/html/93182.html" rel="external">"Snakebites worldwide: Management"</a>.)</p><p class="headingAnchor" id="H3806716192"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115404.html" rel="external">"Society guideline links: Travel medicine"</a>.)</p><p class="headingAnchor" id="H2954329"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Central Africa is comprised of Angola, Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, Gabon, South Sudan, Sudan, Democratic Republic of Congo (Zaire), and Zambia. This region encompasses tropical rain forests, desert areas, and wooded areas. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malaria is a major risk for travelers to Central Africa. Endemic areas exist in all countries in this region. <em>Plasmodium falciparum</em> is the predominant cause of malaria, and <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> resistance is widespread. Within endemic areas, transmission occurs year round. (See <a class="local">'Malaria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other arthropod-borne diseases include yellow fever, dengue, African trypanosomiasis, leishmaniasis, onchocerciasis, and rickettsioses. Other viral hemorrhagic fevers include Ebola virus, Marburg virus, and Crimean-Congo hemorrhagic fever. (See <a class="local">'Arthropod-borne diseases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Foodborne and waterborne diseases include travelers' diarrhea, cholera, typhoid, hepatitis A, hepatitis E, schistosomiasis, paragonimiasis, dracunculiasis, and echinococcosis. (See <a class="local">'Foodborne and waterborne diseases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other infections include meningococcal disease, HIV infection and other sexually transmitted diseases, hepatitis B, hepatitis C, plague, rabies, and tuberculosis. (See <a class="local">'Other infections'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control and Prevention. Malaria Information and Prophylaxis, by Country. https://www.cdc.gov/malaria/travelers/country_table/a.html (Accessed on January 21, 2021).</li><li class="breakAll">Informal Working Group on Geographic Risk of Yellow Fever. Background for the Consultation on Yellow Fever and International Travel, 2010 (update February 2011). World Health Organization, Stockholm, Sweden, 4-5 March 2010.</li><li><a class="nounderline abstract_t">Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis 1999; 179 Suppl 1:ix.</a></li><li><a class="nounderline abstract_t">Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487.</a></li><li><a class="nounderline abstract_t">Heffernan RT, Pambo B, Hatchett RJ, et al. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997. J Infect Dis 2005; 191:964.</a></li><li><a class="nounderline abstract_t">Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575.</a></li><li><a class="nounderline abstract_t">Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006; 355:909.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Outbreak of Marburg virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:308.</a></li><li><a class="nounderline abstract_t">Peters CJ. Marburg and Ebola--arming ourselves against the deadly filoviruses. N Engl J Med 2005; 352:2571.</a></li><li><a class="nounderline abstract_t">Borchert M, Mulangu S, Swanepoel R, et al. Serosurvey on household contacts of Marburg hemorrhagic fever patients. Emerg Infect Dis 2006; 12:433.</a></li><li><a class="nounderline abstract_t">Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012; 2:215.</a></li><li><a class="nounderline abstract_t">Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004; 64:145.</a></li><li><a class="nounderline abstract_t">Ergönül O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006; 6:203.</a></li><li><a class="nounderline abstract_t">Ergönül O, Celikbaş A, Dokuzoguz B, et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39:284.</a></li><li><a class="nounderline abstract_t">Swanepoel R, Shepherd AJ, Leman PA, et al. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa. Am J Trop Med Hyg 1987; 36:120.</a></li><li><a class="nounderline abstract_t">Tufan ZK, Yigit H, Kacar M, et al. Sonographic findings in patients with Crimean-Congo hemorrhagic fever. J Ultrasound Med 2014; 33:1999.</a></li><li><a class="nounderline abstract_t">Shepherd AJ, Swanepoel R, Leman PA. Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11 Suppl 4:S801.</a></li><li><a class="nounderline abstract_t">Fisher-Hoch SP, Khan JA, Rehman S, et al. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995; 346:472.</a></li><li><a class="nounderline abstract_t">Ergonul O, Tuncbilek S, Baykam N, et al. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 2006; 193:941.</a></li><li><a class="nounderline abstract_t">Ponce-de-León S, Lisker-Melman M, Kato-Maeda M, et al. Trypanosoma brucei rhodesiense infection imported to Mexico from a tourist resort in Kenya. Clin Infect Dis 1996; 23:847.</a></li><li><a class="nounderline abstract_t">Pryce D, Behrens R, Davidson R, et al. Onchocerciasis in members of an expedition to Cameroon: role of advice before travel and long term follow up. BMJ 1992; 304:1285.</a></li><li><a class="nounderline abstract_t">Encarnacion CF, Giordano MF, Murray HW. Onchocerciasis in New York City. The Moa-Manhattan connection. Arch Intern Med 1994; 154:1749.</a></li><li><a class="nounderline abstract_t">Mendelson M, Davis XM, Jensenius M, et al. Health risks in travelers to South Africa: the GeoSentinel experience and implications for the 2010 FIFA World Cup. Am J Trop Med Hyg 2010; 82:991.</a></li><li><a class="nounderline abstract_t">Parola P. Rickettsioses in sub-Saharan Africa. Ann N Y Acad Sci 2006; 1078:42.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Chikungunya virus - Geographic Distribution. http://www.cdc.gov/chikungunya/geo/index.html (Accessed on May 01, 2023).</li><li><a class="nounderline abstract_t">Jan C, Languillat G, Renaudet J, Robin Y. [A serological survey of arboviruses in Gabon]. Bull Soc Pathol Exot Filiales 1978; 71:140.</a></li><li><a class="nounderline abstract_t">Saluzzo JF, Ivanoff B, Languillat G, Georges AJ. [Serological survey for arbovirus antibodies in the human and simian populations of the South-East of Gabon (author's transl)]. Bull Soc Pathol Exot Filiales 1982; 75:262.</a></li><li><a class="nounderline abstract_t">Grard G, Caron M, Mombo IM, et al. Zika virus in Gabon (Central Africa)--2007: a new threat from Aedes albopictus? PLoS Negl Trop Dis 2014; 8:e2681.</a></li><li><a class="nounderline abstract_t">Berthet N, Nakouné E, Kamgang B, et al. Molecular characterization of three Zika flaviviruses obtained from sylvatic mosquitoes in the Central African Republic. Vector Borne Zoonotic Dis 2014; 14:862.</a></li><li><a class="nounderline abstract_t">Steffen R. Epidemiology of traveler's diarrhea. Clin Infect Dis 2005; 41 Suppl 8:S536.</a></li><li><a class="nounderline abstract_t">Hyams KC, Purdy MA, Kaur M, et al. Acute sporadic hepatitis E in Sudanese children: analysis based on a new western blot assay. J Infect Dis 1992; 165:1001.</a></li><li><a class="nounderline abstract_t">Jelinek T, Nothdurft HD, Löscher T. Schistosomiasis in Travelers and Expatriates. J Travel Med 1996; 3:160.</a></li><li class="breakAll">World Health Organization. Dracunculiasis (guinea-worm disease). https://www.who.int/news-room/fact-sheets/detail/dracunculiasis-(guinea-worm-disease) (Accessed on January 21, 2021).</li><li><a class="nounderline abstract_t">Eng TR, O'Brien TR, Bernard KW, et al. HIV-1 and HIV-2 Infections Among U.S. Peace Corps Volunteers Returning from West Africa. J Travel Med 1995; 2:174.</a></li><li><a class="nounderline abstract_t">Cleaveland S. Royal Society of Tropical Medicine and Hygiene meeting at Manson House, London, 20 March 1997. Epidemiology and control of rabies. The growing problem of rabies in Africa. Trans R Soc Trop Med Hyg 1998; 92:131.</a></li></ol></div><div id="topicVersionRevision">Topic 96985 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/malaria/travelers/country_table/a.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control and Prevention. Malaria Information and Prophylaxis, by Country. https://www.cdc.gov/malaria/travelers/country_table/a.html (Accessed on January 21, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Informal Working Group on Geographic Risk of Yellow Fever. Background for the Consultation on Yellow Fever and International Travel, 2010 (update February 2011). World Health Organization, Stockholm, Sweden, 4-5 March 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988154" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An introduction to Ebola: the virus and the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288821" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pathogenesis of filoviral haemorrhagic fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15717273" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319873" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fruit bats as reservoirs of Ebola virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943403" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Marburg hemorrhagic fever associated with multiple genetic lineages of virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800477" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outbreak of Marburg virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972860" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Marburg and Ebola--arming ourselves against the deadly filoviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704781" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serosurvey on household contacts of Marburg hemorrhagic fever patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22482717" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15550268" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Crimean-Congo hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554245" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Crimean-Congo haemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307042" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3101525" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25336488" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sonographic findings in patients with Crimean-Congo hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2501854" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antibody response in Crimean-Congo hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637481" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Crimean Congo-haemorrhagic fever treated with oral ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518755" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909868" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Trypanosoma brucei rhodesiense infection imported to Mexico from a tourist resort in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1606433" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Onchocerciasis in members of an expedition to Cameroon: role of advice before travel and long term follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8042892" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Onchocerciasis in New York City. The Moa-Manhattan connection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519590" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Health risks in travelers to South Africa: the GeoSentinel experience and implications for the 2010 FIFA World Cup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114679" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rickettsioses in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114679" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rickettsioses in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/743766" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : [A serological survey of arboviruses in Gabon].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6809352" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : [Serological survey for arbovirus antibodies in the human and simian populations of the South-East of Gabon (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24516683" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Zika virus in Gabon (Central Africa)--2007: a new threat from Aedes albopictus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25514122" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Molecular characterization of three Zika flaviviruses obtained from sylvatic mosquitoes in the Central African Republic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267715" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Epidemiology of traveler's diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1583317" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute sporadic hepatitis E in Sudanese children: analysis based on a new western blot assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815445" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Schistosomiasis in Travelers and Expatriates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815445" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Schistosomiasis in Travelers and Expatriates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815380" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : HIV-1 and HIV-2 Infections Among U.S. Peace Corps Volunteers Returning from West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764313" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Royal Society of Tropical Medicine and Hygiene meeting at Manson House, London, 20 March 1997. Epidemiology and control of rabies. The growing problem of rabies in Africa.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
